^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
triptorelin
i
Other names: AY 25650, BIM 21003, BN 52014, CL 118532, Debio 8206, Debio 8206 CPP, Debio 8206 SC, WY 42422
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Generic mfg.
Drug class:
GnRH agonist
Related drugs:
3d
Study on Human Bioequivalence of Triprerelin Acetate for Injection (clinicaltrials.gov)
P1, N=120, Recruiting, The Affiliated Hospital of Qingdao University
New P1 trial
|
triptorelin
10d
EORTC-1206: Androgen Deprivation Therapy in Advanced Salivary Gland Cancer (clinicaltrials.gov)
P2, N=149, Completed, European Organisation for Research and Treatment of Cancer - EORTC | Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Feb 2024
Trial completion • Trial completion date • Metastases
|
AR expression
|
cisplatin • carboplatin • paclitaxel • doxorubicin hydrochloride • bicalutamide • triptorelin
14d
REAL6T: A Study to Observe Demography and the Outcome of Prostate Cancer Patients Treated With 6-month Triptorelin Formulation in Italy (clinicaltrials.gov)
P=N/A, N=167, Completed, Ipsen | Recruiting --> Completed | N=300 --> 167
Trial completion • Enrollment change
|
triptorelin
1m
ROSE: Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment (clinicaltrials.gov)
P=N/A, N=419, Recruiting, Ipsen | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2025 --> Mar 2026
Trial completion date • Trial primary completion date • HEOR
|
HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
|
BRCA1 mutation • HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation • PTEN mutation + HR positive
|
triptorelin
2ms
BOUQUET: A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (clinicaltrials.gov)
P2, N=176, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Dec 2028 --> May 2028 | Trial primary completion date: May 2028 --> Feb 2028
Trial completion date • Trial primary completion date
|
ER (Estrogen receptor)
|
Avastin (bevacizumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • paclitaxel • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • cyclophosphamide • letrozole • ipatasertib (RG7440) • triptorelin • goserelin acetate • Itovebi (inavolisib) • giredestrant (GDC-9545)
2ms
HypoFocal SRT: Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical Prostatectomy (clinicaltrials.gov)
P=N/A, N=36, Recruiting, Insel Gruppe AG, University Hospital Bern | Phase classification: P2 --> P=N/A
Phase classification
|
bicalutamide • triptorelin
2ms
LIBELULA: A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (clinicaltrials.gov)
P3, N=53, Recruiting, Debiopharm International SA | Trial completion date: Sep 2027 --> Dec 2027
Trial completion date
|
triptorelin
2ms
Adenomyosis and Pregnancy: Levonorgestrel vs. GnRH for Blastocyst Transfer (clinicaltrials.gov)
P=N/A, N=184, Completed, Zagazig University
New trial
|
triptorelin
3ms
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate (clinicaltrials.gov)
P3, N=195, Completed, Ipsen | Active, not recruiting --> Completed
Trial completion • Metastases
|
triptorelin
3ms
REAL6T: A Study to Observe Demography and the Outcome of Prostate Cancer Patients Treated With 6-month Triptorelin Formulation in Italy (clinicaltrials.gov)
P=N/A, N=300, Recruiting, Ipsen | Trial completion date: Jun 2024 --> Sep 2024 | Trial primary completion date: Jun 2024 --> Sep 2024
Trial completion date • Trial primary completion date
|
triptorelin
4ms
Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate (clinicaltrials.gov)
P3, N=147, Completed, Ipsen | Active, not recruiting --> Completed
Trial completion • Metastases
|
triptorelin
4ms
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer (clinicaltrials.gov)
P2, N=32, Not yet recruiting, OHSU Knight Cancer Institute
New P2 trial • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • bicalutamide • triptorelin • goserelin acetate • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension
4ms
Potential therapeutic properties of broccoli extract and soy isoflavones on improvement endometriosis and involved oxidative parameters. (PubMed, Horm Mol Biol Clin Investig)
BE in combination with SI decreased the growth and histopathologic grades of transplanted endometrial implants. These herbal compounds may have the potential therapeutic effect to be used as an alternative medication for the treatment of endometriosis.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha)
|
triptorelin
4ms
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer (clinicaltrials.gov)
P2, N=32, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting | Trial completion date: Jan 2027 --> Jul 2028 | Trial primary completion date: Jan 2027 --> Jul 2027
Enrollment closed • Trial completion date • Trial primary completion date • Metastases
|
docetaxel • Tevimbra (tislelizumab-jsgr) • Xtandi (enzalutamide capsule) • abiraterone acetate • triptorelin • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension
4ms
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer (clinicaltrials.gov)
P3, N=60, Not yet recruiting, Children's Oncology Group
New P3 trial
|
triptorelin
4ms
CDK4/6 and aromatase inhibitors as first-line treatment in metastatic high-grade neuroendocrine carcinoma of the breast: A case report. (PubMed, Clin Case Rep)
Herein, we present the first case ever reported, concerning a female patient with de novo metastatic breast NEC who received hormonal therapy, a combination of a CDK4/6 inhibitor palbociclib with letrozole and triptorelin, as first-line treatment with significant clinical and radiological response. As most NECs are estrogen receptor and/or progesterone receptor positive and HER-2 negative, we suggest that hormonal therapy may play a leading role even in the first-line setting. The present report provides a new treatment strategy by incorporating CDK4/6 inhibitors in the therapeutic armamentarium of breast NECs.
Journal • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
Ibrance (palbociclib) • letrozole • triptorelin
4ms
PRIMORDIUM: A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (clinicaltrials.gov)
P3, N=694, Active, not recruiting, Janssen Pharmaceutica N.V., Belgium | Recruiting --> Active, not recruiting | N=412 --> 694
Enrollment closed • Enrollment change
|
Erleada (apalutamide) • triptorelin • goserelin acetate
4ms
Gonadotropin-releasing Hormone (GnRH) Downregulation Versus Oral Anticonception Prior to ART in Postoperative Endometriosis Patients (clinicaltrials.gov)
P=N/A, N=166, Completed, Universitaire Ziekenhuizen KU Leuven | Unknown status --> Completed
Trial completion
|
triptorelin
4ms
Efficacy, Metabolism and BMD of the 3-month TP Compared to the 1-month TP in ICPP (clinicaltrials.gov)
P4, N=134, Not yet recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
New P4 trial
|
triptorelin
5ms
Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial (clinicaltrials.gov)
P2, N=120, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
Xtandi (enzalutamide capsule) • abiraterone acetate • Nubeqa (darolutamide) • Erleada (apalutamide) • triptorelin • goserelin acetate • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension
5ms
PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study (clinicaltrials.gov)
P4, N=60, Not yet recruiting, University Hospital, Ghent | Initiation date: Apr 2024 --> Jul 2024
Trial initiation date
|
triptorelin
6ms
LIBELULA: A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (clinicaltrials.gov)
P3, N=53, Recruiting, Debiopharm International SA | Initiation date: Apr 2024 --> Jul 2024
Trial initiation date
|
triptorelin
6ms
BOUQUET: A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (clinicaltrials.gov)
P2, N=176, Active, not recruiting, Hoffmann-La Roche | N=550 --> 176
Enrollment change
|
ER (Estrogen receptor)
|
Avastin (bevacizumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • paclitaxel • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • cyclophosphamide • letrozole • ipatasertib (RG7440) • triptorelin • goserelin acetate • Itovebi (inavolisib) • giredestrant (GDC-9545)
6ms
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer (clinicaltrials.gov)
P2, N=19, Active, not recruiting, University of Colorado, Denver | Trial completion date: Apr 2024 --> Apr 2025
Trial completion date
|
Xtandi (enzalutamide capsule) • triptorelin • goserelin acetate • Firmagon (degarelix) • leuprolide acetate for depot suspension
7ms
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland (clinicaltrials.gov)
P=N/A, N=1, Completed, Pfizer | Trial completion date: Jun 2023 --> Apr 2024 | Trial primary completion date: Jun 2023 --> Apr 2024
Trial completion date • Trial primary completion date • HEOR • Real-world evidence • Real-world • Metastases
|
docetaxel • Xtandi (enzalutamide capsule) • abiraterone acetate • cabazitaxel • Erleada (apalutamide) • triptorelin • goserelin acetate • Firmagon (degarelix) • Xofigo (radium Ra-223 dichloride) • leuprolide acetate for depot suspension
7ms
Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial (clinicaltrials.gov)
P2, N=120, Not yet recruiting, Mayo Clinic
New P2 trial • Metastases
|
Xtandi (enzalutamide capsule) • abiraterone acetate • Nubeqa (darolutamide) • Erleada (apalutamide) • triptorelin • goserelin acetate • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension
7ms
BOUQUET: A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (clinicaltrials.gov)
P2, N=550, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
Enrollment closed
|
ER (Estrogen receptor)
|
Avastin (bevacizumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • paclitaxel • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • cyclophosphamide • letrozole • ipatasertib (RG7440) • triptorelin • goserelin acetate • Itovebi (inavolisib) • giredestrant (GDC-9545)
7ms
Micro RNAs to Predict Response to Androgen Deprivation Therapy (clinicaltrials.gov)
P=N/A, N=42, Active, not recruiting, Medical College of Wisconsin | N=60 --> 42
Enrollment change
|
docetaxel • Xtandi (enzalutamide capsule) • abiraterone acetate • bicalutamide • Erleada (apalutamide) • triptorelin • goserelin acetate • leuprolide acetate for depot suspension
7ms
EORTC-1532: ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer (clinicaltrials.gov)
P2, N=61, Active, not recruiting, European Organisation for Research and Treatment of Cancer - EORTC | Trial completion date: May 2024 --> Dec 2036
Trial completion date
|
Nubeqa (darolutamide) • triptorelin • goserelin acetate • Firmagon (degarelix)
8ms
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate (clinicaltrials.gov)
P3, N=195, Active, not recruiting, Ipsen | Recruiting --> Active, not recruiting
Enrollment closed • Metastases
|
triptorelin
8ms
PRIMORDIUM: A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (clinicaltrials.gov)
P3, N=412, Recruiting, Janssen Pharmaceutica N.V., Belgium | Trial completion date: Jan 2030 --> Aug 2029 | Trial primary completion date: Jan 2030 --> Aug 2029
Trial completion date • Trial primary completion date
|
Erleada (apalutamide) • triptorelin • goserelin acetate
9ms
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate (clinicaltrials.gov)
P3, N=195, Recruiting, Ipsen | Trial completion date: Jul 2024 --> Oct 2024 | Trial primary completion date: Jul 2024 --> Oct 2024
Trial completion date • Trial primary completion date • Metastases
|
triptorelin
9ms
LIBELULA: A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (clinicaltrials.gov)
P3, N=53, Recruiting, Debiopharm International SA | Not yet recruiting --> Recruiting
Enrollment open
|
triptorelin
9ms
THUNDER: Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (clinicaltrials.gov)
P2/3; N=493; Recruiting; Sponsor:Cancer Research Antwerp
New P2/3 trial
|
Decipher Prostate Cancer Test
|
docetaxel • Eligard (leuprolide acetate) • Nubeqa (darolutamide) • triptorelin • goserelin acetate • Firmagon (degarelix)
9ms
Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer (clinicaltrials.gov)
P1, N=17, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Phase classification: P1b --> P1
Phase classification
|
abiraterone acetate • prednisone • triptorelin • goserelin acetate
9ms
ROSE: Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment (clinicaltrials.gov)
P=N/A, N=419, Recruiting, Ipsen | Trial primary completion date: Jun 2024 --> Dec 2025
Trial primary completion date • HEOR
|
HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
|
BRCA1 mutation • HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation • PTEN mutation + HR positive
|
triptorelin
9ms
LadyDe: Luteal Phase Ovarian Stimulation With Follitropin Delta and Dydrogesterone (clinicaltrials.gov)
P=N/A, N=50, Recruiting, CRG UZ Brussel | Trial completion date: May 2024 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
Trial completion date • Trial primary completion date
|
triptorelin
9ms
SAVE: Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP (clinicaltrials.gov)
P2, N=202, Recruiting, Cancer Research Antwerp | Trial completion date: Sep 2022 --> Dec 2025 | Trial primary completion date: Dec 2021 --> Aug 2025
Trial completion date • Trial primary completion date • Combination therapy
|
Erleada (apalutamide) • triptorelin • goserelin acetate • Firmagon (degarelix) • leuprolide acetate for depot suspension
9ms
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer (clinicaltrials.gov)
P2, N=31, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Phase classification: P2a --> P2 | Trial completion date: May 2026 --> Jan 2027 | Trial primary completion date: May 2025 --> Jan 2027
Phase classification • Trial completion date • Trial primary completion date • Metastases
|
docetaxel • Tevimbra (tislelizumab-jsgr) • Xtandi (enzalutamide capsule) • abiraterone acetate • triptorelin • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension
9ms
SOLTI-2104: Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer (clinicaltrials.gov)
P2, N=48, Recruiting, SOLTI Breast Cancer Research Group | Not yet recruiting --> Recruiting
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • HER-2 expression
|
Orserdu (elacestrant) • triptorelin
9ms
A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer (clinicaltrials.gov)
P=N/A, N=960, Completed, Bayer | Active, not recruiting --> Completed
Trial completion
|
docetaxel • Xtandi (enzalutamide capsule) • abiraterone acetate • Eligard (leuprolide acetate) • triptorelin • goserelin acetate • cyproterone acetate
10ms
Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support (clinicaltrials.gov)
P4, N=75, Completed, Alexandria University | Recruiting --> Completed
Trial completion
|
triptorelin
Share via
